Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature
- PMID: 25336875
- PMCID: PMC4201398
Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature
Abstract
Objectives: We present the clinical outcome and long-term survival in patients with medullary thyroid carcinoma treated in a tertiary center. A thorough review of published series and current therapeutic approaches is also addressed.
Study design: A retrospective review.
Setting: An Academic Tertiary center.
Subjects/methods: An analysis of oncologic outcomes from 25 patients treated in our department for medullary thyroid carcinoma is performed, together with a comparison of relevant studies over the literature.
Results: The incidence of patients alive free of disease and the 5-year survival rate has been noticed to be slightly higher than the rate reported in most series.
Conclusions: Total thyroidectomy and neck dissection remains the gold standard in the treatment of medullary thyroid carcinoma. Early diagnosis and aggressive surgical treatment lead to lower rates of recurrence and invasiveness. Tyrosine-kinase inhibitor, especially vantetanib, appears to be a promising target for treatment.
Keywords: Medullary thyroid carcinoma; Tyrosine-kinase inhibitor; calcitonin; neck dissection; sporadic; thyroidectomy.
Similar articles
-
Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.G Chir. 2012 Nov-Dec;33(11-12):395-9. G Chir. 2012. PMID: 23140924
-
[Surgical treatment and prognosis analysis on medullary thyroid carcinoma].Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Mar;46(3):209-13. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011. PMID: 21575412 Chinese.
-
Medullary thyroid carcinoma: long-term outcomes of surgical treatment.Ann Surg Oncol. 2011 Jan;18(1):219-25. doi: 10.1245/s10434-010-1339-y. Epub 2010 Sep 28. Ann Surg Oncol. 2011. PMID: 20878247
-
Surgical treatment of medullary carcinoma of the thyroid.Otolaryngol Clin North Am. 1990 Jun;23(3):453-73. Otolaryngol Clin North Am. 1990. PMID: 1973281 Review.
-
An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.Gulf J Oncolog. 2020 Sep;1(34):39-47. Gulf J Oncolog. 2020. PMID: 33431361 Review.
Cited by
-
Anti-tumor effects of shikonin derivatives on human medullary thyroid carcinoma cells.Endocr Connect. 2017 Feb;6(2):53-62. doi: 10.1530/EC-16-0105. Epub 2017 Jan 9. Endocr Connect. 2017. PMID: 28069896 Free PMC article.
-
Somatostatin and Somatostatin Receptors in Tumour Biology.Int J Mol Sci. 2023 Dec 28;25(1):436. doi: 10.3390/ijms25010436. Int J Mol Sci. 2023. PMID: 38203605 Free PMC article. Review.
-
Medullary thyroid cancer: epidemiological pattern and factors contributing to recurrence and metastasis.Ann R Coll Surg Engl. 2020 Sep;102(7):499-503. doi: 10.1308/rcsann.2020.0056. Epub 2020 Apr 1. Ann R Coll Surg Engl. 2020. PMID: 32233867 Free PMC article.
-
Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.J Endocrinol Invest. 2021 Sep;44(9):1837-1846. doi: 10.1007/s40618-020-01456-6. Epub 2021 Feb 11. J Endocrinol Invest. 2021. PMID: 33575974
References
-
- Carney JA. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol. 2005;29:254–274. - PubMed
-
- Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–460. - PubMed
-
- Wells SA, Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009;15:7119–7123. - PubMed
-
- Gkountouvas A, Nikas M, Chatjimarkou F, Thomas D, Georgiadis P, Kaldrimidis P. Thyroid cancer in Greece. A tertiary center experience. J BUON. 2010;15:674–678. - PubMed
LinkOut - more resources
Full Text Sources